ACCME clarifies symposia-fee rule

Share this article:

The ACCME clarified its rule on management and reporting of payments to reserve space for satellite symposia.

Payments made by pharma or device firms to hold space for satellite activities, which are accredited CME activities held in conjunction with medical meetings, constitute commercial support and must be made directly to the accredited provider responsible for the activity or a designated non-accredited joint sponsor, the ACCME said.

The clarification, reported by  ACCME in January as part of minutes from its November 2012 board meeting, is effective going forward, the watchdog said.

Many medical societies, in order to assure that satellite symposia would have funding, have required commercial supporters to pay them the symposium fee in advance. That practice was at odds with ACCME standards, which require grantors to hand over any commercial monies to outside CME providers to manage the process as a way to prevent bias.

The clarity “aligns with how commercial supporters have been handling and reporting these fees as part of the independent education grant for a number of years,” said Pamela Mason, director, Medical Education Grants Office, AstraZeneca. “Clarifying how satellite reservation (slot) fees are to be managed and reported as commercial support is important because there will be a more transparent and consistent accounting of the funds by the grantor and accredited provider.”
Share this article:
close

Next Article in Features

Email Newsletters

More in Features

Headliner: Proteus CEO takes an original path

Headliner: Proteus CEO takes an original path

Andrew Thompson, CEO, Proteus Digital Health

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...